The research and development projects implemented by the Company,
in accordance with the decision of the Management Board of April 3, 2019 are classified into the following three groups:
This is a group of projects of the greatest importance for the Company, as part of which the Company carries out work and
invests funds. The group includes projects currently under way: MabionCD20, MabionMS and MabionEGFR.
The projects for which the Company started research and development work in 2019 are three biosimilar drugs in the area of
autoimmunity, metabolic diseases and oncology (denosumab and omalizumab antibodies). At present, a significant part of the
team responsible for the development of the aforementioned antibodies has been assigned to support the Company's priority
projects (MabionCD20 and Novavax), in connection with the need to carry out work related to the development and optimisation
of the process, as well as analytical and manufacturing work.
These are the projects for which the Company considers starting implementation in the mid or long term, preferably in
cooperation with a partner. The projects will concern, inter alia, autoimmune and oncological, or rare diseases.
As part of the partnership projects, the Company has undertaken the following activities:
- Signing a letter of intent with IcanoMAB GmbH regarding potential collaboration to conduct CMC (Chemistry, Manufacturing and Controls) type development and manufacturing of a human IL-1R7 mAb antibody under development by IcanoMAB asa potential drug to treat patients with COVID-19 infection (October 2020);
- Signing of a Memorandum of Understanding with Taxon Therapeutics Ltd. regarding cooperation in the research, development, and commercialisation of MabionCD20 antibody drug in specific clinical indications in the area of rare diseases (October 2020);
- Entering into a framework agreement together with the first order for contractual services with Novavax, Inc. under which the Company, with Novavax’s participation, will undertake activities related to the transfer of the manufacturing process technology and antigen analytics of the vaccine candidate for COVID-19 under the working name of NVX-CoV2373 and will carry out technical trial runs of the process on a commercial scale at the Company’s facility (March 2021).